SC 13G/A 1 i020823a.htm SCHEDULE 13G (AMENDMENT NO. 1)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

AMENDMENT NO. 1

Under the Securities Exchange Act of 1934

Ibere Pharmaceuticals

(Name of Issuer)

Class A Ordinary Share, par value $0.0001 per share

(Title of Class of Securities)

G46843127

(CUSIP Number)

12/31/2022

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[_] Rule 13d-1(b)

[X] Rule 13d-1(c)

[_] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G

CUSIP No.

G46843127

1	Names of Reporting Persons
	Hartree Partners, LP
2	Check the appropriate box if a member of a Group (see instructions)
	(a) [] (b) [X]
3	Sec Use Only

4	Citizenship or Place of Organization
	Delaware, United States of America
Number of Shares Beneficially Owned by Each Reporting Person With:		5	Sole Voting Power
			0
		6	Shared Voting Power
			0
		7	Sole Dispositive Power
			0
		8	Shared Dispositive Power
			0
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	0
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	[ ]
11	Percent of class represented by amount in row (9)
	0%
12	Type of Reporting Person (See Instructions) PN, Partnership

Item 1.

(a) Name of Issuer:

Ibere Pharmaceuticals

(b) Address of Issuer’s Principal Executive Offices:

2005 Market Street, Suite 2030, Philadelphia, PA 19103

Item 2.

(a)	Name of Person Filing:

Hartree Partners, LP

(b)	Address of Principal Business Office or, if None, Residence:

1185 Avenue of the Americas

New York, NY 10036

Citizenship:

United States of America

(c)	Title and Class of Securities:

Class A ordinary share, par value $0.0001 per share

(d)	CUSIP No.: G46843127

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

[_]

Broker or dealer registered under Section 15 of the Act;

(b)

[_]

Bank as defined in Section 3(a)(6) of the Act;

(c)

[_]

Insurance company as defined in Section 3(a)(19) of the Act;

(d)

[_]

Investment company registered under Section 8 of the Investment Company Act of 1940;

(e)

[_]

An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f)

[_]

An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

(g)

[_]

A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h)

[_]

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

[_]

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

(j)

[_]

A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

(k)

[_]

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4. Ownership

(a)	Amount Beneficially Owned:

(b) Percent of Class:

0% based upon a total number of Class A ordinary shares, par value $0.0001 per share, outstanding of 13,800,000 on November 14, 2022, as reported by Ibere Pharmaceuticals in its Annual Report on Form 10Q, dated November 14, 2022.

(i) Sole power to vote or to direct the vote:

(ii) Shared power to vote or to direct the vote:

(iii)

Sole power to dispose or to direct the disposition of:

(iv)	Shared power to dispose or to direct the disposition of:

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].

Item 6.

Ownership of more than Five Percent on Behalf of Another Person.

N/A

Item 7.

Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

N/A

Item 8.

Identification and classification of members of the group.

N/A

Item 9. Notice of Dissolution of Group.

N/A

Item 10.

Certifications.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 8, 2023

/s/ Christine Stevenson

Name: Christine Stevenson

Title: Chief Compliance Officer

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)